fda compounding semaglutide crackdown news today 2025 The is drawing a harder line on compounded weight loss drug marketing. In the May–June 2026 issue of Dispense Times, this article breaks down key violations cited in recent FDA enforcement FDA is cracking down on

And in the STEP 3 trial, participants who received semaglutide 2.4 mg plus intensive behavioral therapy lost an average of 16.0% of their bodyweight (as compared to 5.7% in the placebo group)

You don't need to go to Emory, but Emory-trained clinicians spread across Atlanta's private practices raise the quality floor for the whole market

ACOG states the FDA/Department of Health and Human Services (HHS) announcements are not supported by the full body of scientific evidence and simplifies the multifactorial, complex causes of neurological problems in children

The cost difference between a modest rating and the next step up might be small compared to the extended lifespan and reduced risk of damage